Dynavax Technologies (DVAX) Stock Price
Dynavax Technologies Price
Revenue has compounded at 16.7% per year over the past 19 years to 277.25 M USD. Earnings per share have declined at 33.8% per year over the last 3 years. Dynavax Technologies's net margin stands at 9.9%, up from -161.6% several years earlier. Analysts set a median price target of 20.91 USD, implying 34.9% above the current price. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus.
Dynavax Technologies stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Dynavax Technologies business model & stock analysis
Frequently asked questions about Dynavax Technologies
The business model of Dynavax Technologies Corp focuses on developing and commercializing innovative vaccines to address critical unmet medical needs. As a biopharmaceutical company, Dynavax utilizes its expertise in immunology to create novel vaccines that target diseases such as hepatitis B, pertussis, and the flu. Through strategic partnerships and collaborations, the company aims to advance its vaccine candidates and bring them to market. Dynavax's business model is centered around research and development, regulatory approvals, and successful commercialization of their vaccine products to improve public health and provide value to shareholders.
Dynavax Technologies Corp is primarily active in the biotechnology industry. As a reputable company in the stock market, Dynavax Technologies Corp focuses on developing and commercializing novel vaccines and therapeutics. With its innovative approaches to immunology, the company addresses pressing medical needs in areas such as infectious diseases, oncology, and autoimmune disorders. With a strong presence in the biotechnology sector, Dynavax Technologies Corp consistently strives to revolutionize the healthcare industry through groundbreaking advancements.
The main competitors of Dynavax Technologies Corp in the market are companies like GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co., Inc., and Pfizer Inc. These pharmaceutical giants operate in similar fields as Dynavax and offer competitive products and services. However, Dynavax Technologies Corp distinguishes itself through its innovative approach, cutting-edge technologies, and continuous research and development efforts. As a result, Dynavax has successfully carved out its space in the market, offering unique solutions and contributing to advancements in the healthcare industry.
Dynavax Technologies Corp is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of innovative vaccines and immunotherapies. Established in 1996, Dynavax has a rich history of pioneering research in the field of immunology. The company has made significant advancements in novel vaccine platforms, including DNA-based vaccines and Toll-like Receptor (TLR) agonists. With a strong focus on improving patient outcomes, Dynavax has successfully developed and brought to market several FDA-approved vaccines, such as HEPLISAV-B® for hepatitis B. Dynavax Technologies Corp continues to drive advancements in the field of immunotherapy, aiming to combat infectious diseases and achieve better global health outcomes.
Dynavax Technologies Corp has achieved several significant milestones. One notable milestone is the FDA approval of their vaccine HEPLISAV-B for the prevention of hepatitis B infection in adults. This approval marked a major breakthrough, as HEPLISAV-B demonstrated superior efficacy compared to existing vaccines. Additionally, the company successfully completed clinical trials for SD-101, an investigational cancer immunotherapy. These trials demonstrated promising results, potentially opening new avenues for treating various cancers. Furthermore, Dynavax Technologies Corp secured partnerships with renowned pharmaceutical companies, facilitating the development and commercialization of their innovative products. These achievements highlight the company's dedication to advancing healthcare solutions and driving growth in the biopharmaceutical industry.
Dynavax Technologies Corp is primarily present in the United States.
Dynavax Technologies Corp represents values of innovation, dedication, and excellence in the biotechnology industry. With a strong corporate philosophy centered around improving patient outcomes and enhancing global health, Dynavax is committed to developing and commercializing novel vaccines for the prevention and treatment of infectious diseases. By leveraging cutting-edge science and advanced technologies, the company aims to address unmet medical needs and contribute to the well-being of communities worldwide. Dynavax Technologies Corp continuously strives to provide groundbreaking solutions and foster a culture of collaboration and scientific rigor in its pursuit of improving public health.
Analysts currently set an average price target of 20.91 USD for the Dynavax Technologies stock (median: 20.91 USD), implying +34.9 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Dynavax Technologies stock: 7 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Dynavax Technologies share trades at 13.85 EUR (15.50 USD).
The Dynavax Technologies share (DVAX) is listed on 7 stock exchanges, including: NASDAQ (DVAX), London (0IDA.L), SIX (Zürich) (DYF1.SW), Frankfurt (DYF1.F), München (DYF1.MU), Düsseldorf (DYF1.DU).
Dynavax Technologies Corp is a biopharmaceutical company that focuses on the development of vaccines for various diseases. The company is headquartered in Emeryville, California and was founded in 1996. Dynavax has become a leading provider of vaccines in the market in recent years. The business model of Dynavax includes research, development, manufacturing, and marketing of vaccines for various diseases. One of its key products is the Heplisav-B vaccine. Heplisav-B is a Hepatitis B vaccine approved for the prevention of Hepatitis B infections in adults. In addition, the company also has other products in development. These include vaccines for rabies, pneumonia, and Hepatitis C. Dynavax has also developed a platform technology called SICCAR, which enables the production of fast-acting vaccines. Dynavax has different divisions focused on the development of vaccines for different diseases. The main divisions of the company are Hepatitis B vaccines, rabies vaccines, pneumonia vaccines, and Hepatitis C vaccines. Additionally, Dynavax is also developing vaccines for other diseases such as cancer. Dynavax's business model also includes partnerships with other companies for the joint development and marketing of vaccines. The company collaborates with major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca to develop vaccines for various diseases. Dynavax also utilizes its platform technology to develop vaccines for partner companies. The company also relies on geographical expansion to expand the market for its products. Dynavax has opened branches in Europe and Asia to strengthen its presence in the global market. This has allowed the company to sell its products in other parts of the world and attract new customers. Overall, Dynavax's business model is focused on the development and marketing of vaccines for various diseases. The company relies on a wide range of products and offers a platform technology to enable faster vaccine development. Dynavax has also embraced partnerships and geographical expansion to expand its market share and broaden the opportunities for its products.
The revenue cannot currently be calculated for Dynavax Technologies.
The expected profit of Dynavax Technologies is 51.16 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dynavax Technologies is currently 46.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dynavax Technologies stock.
The P/S cannot be calculated for Dynavax Technologies currently.
The Eulerpool Quality Score for Dynavax Technologies is 3/10.
The ISIN of Dynavax Technologies is US2681582019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Dynavax Technologies is A12EV9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Dynavax Technologies is DVAX. The ticker symbol is used to trade Dynavax Technologies shares on the stock exchange.
Dynavax Technologies stock
Dynavax Technologies Peer Group
Dynavax Technologies Ticker
Dynavax Technologies FIGI
All fundamentals and in-depth analysis of Dynavax Technologies
Our stock analysis for Dynavax Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dynavax Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.